A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Adolescent
Adoptive Transfer
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Child
Child, Preschool
Consolidation Chemotherapy
Cyclophosphamide
/ administration & dosage
Disease-Free Survival
Drug Administration Schedule
Female
Humans
Infant
Interleukin-2
/ administration & dosage
Killer Cells, Natural
/ transplantation
Leukemia, Myeloid, Acute
/ therapy
Male
Transplantation, Haploidentical
/ methods
Vidarabine
/ administration & dosage
Acute myeloid leukemia
Child
Clinical trial
Natural killer cells
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
20 03 2019
20 03 2019
Historique:
received:
31
10
2018
accepted:
12
03
2019
entrez:
22
3
2019
pubmed:
22
3
2019
medline:
17
6
2020
Statut:
epublish
Résumé
Consolidation therapies for children with intermediate- or high-risk acute myeloid leukemia (AML) are urgently needed to achieve higher cure rates while limiting therapy-related toxicities. We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. Patients received cyclophosphamide (Day - 7), fludarabine (Days - 6 through - 2), and subcutaneous interleukin-2 (Days - 1, 1, 3, 5, 7, and 9). Purified, unmanipulated NK cells were infused on Day 0, and NK cell chimerism and phenotyping from peripheral blood were performed on Days 7, 14, 21, and 28. As primary endpoint, the event-free survival was compared to a cohort of 55 patients who completed chemotherapy and were in first complete remission but did not receive NK cells. Donor NK cell kinetics were determined as secondary endpoints. Twenty-one patients (median age at diagnosis, 6.0 years [range, 0.1-15.3 years]) received a median of 12.5 × 10
Identifiants
pubmed: 30894213
doi: 10.1186/s40425-019-0564-6
pii: 10.1186/s40425-019-0564-6
pmc: PMC6425674
doi:
Substances chimiques
Interleukin-2
0
Cyclophosphamide
8N3DW7272P
Vidarabine
FA2DM6879K
fludarabine
P2K93U8740
Banques de données
ClinicalTrials.gov
['NCT00703820']
Types de publication
Clinical Trial, Phase II
Comparative Study
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Subventions
Organisme : NCI NIH HHS
ID : P30 CA021765
Pays : United States
Références
J Clin Oncol. 2014 Sep 20;32(27):3021-32
pubmed: 25092781
Blood. 2009 Mar 26;113(13):3119-29
pubmed: 18945967
Blood. 2007 Jul 1;110(1):433-40
pubmed: 17371948
Br J Haematol. 1997 Jun;97(4):855-64
pubmed: 9217189
Pediatr Blood Cancer. 2015 Aug;62(8):1468-72
pubmed: 25925135
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Methods Mol Biol. 2016;1441:175-93
pubmed: 27177666
J Clin Oncol. 2010 Feb 20;28(6):955-9
pubmed: 20085940
Clin Cancer Res. 2018 Apr 15;24(8):1834-1844
pubmed: 29444931
Lancet Oncol. 2010 Jun;11(6):543-52
pubmed: 20451454
Blood. 2017 Oct 19;130(16):1857-1868
pubmed: 28835441
Blood. 2015 Jan 29;125(5):784-92
pubmed: 25452614
Leukemia. 2015 Aug;29(8):1637-47
pubmed: 25721896
Lancet. 2000 Nov 25;356(9244):1795-9
pubmed: 11117911
Annu Rev Immunol. 2002;20:217-51
pubmed: 11861603
Nat Rev Immunol. 2003 May;3(5):413-25
pubmed: 12766763
Bone Marrow Transplant. 2001 Sep;28(5):511-8
pubmed: 11593326
Cancer Res. 2009 May 1;69(9):4010-7
pubmed: 19383914
Immunology. 2007 Jun;121(2):258-65
pubmed: 17346281
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007
Blood. 2011 Sep 22;118(12):3273-9
pubmed: 21791425